We are proud to say that behind BlinkLab's progress is a very talented team working across different disciplines. During our recent gathering, members of the team led a series of seminars, sharing their work, experience, and perspectives from various areas of the company. It was a great chance to learn from one another, something we value highly here at BlinkLab.

Our Managing Director and CEO, Dr. Henk-Jan Boele, presented at the 2026 Neurowrx International Conference, currently taking place in Eindhoven, the Netherlands. The conference brings together people and organizations from around the world to share ideas and approaches to expanding meaningful employment opportunities for autistic and neurodivergent people in STEAM. Dr. Boele shared BlinkLab's journey, including key milestones and achievements, and spoke about what lies ahead for the company.

On August 17, we marked five years since BlinkLab was founded 🚀 From a @Princeton University startup to a growing #medtech company, these years have brought major scientific, clinical, and organizational milestones. To celebrate this milestone, members of our board and investors recently joined the team at our office in Leiden. Thank you to our team, board, investors, collaborators, supporters, and everyone who has helped shape this journey and continues to be part of BlinkLab’s story!

Our #iOS developer, Alex Antonov, was invited to speak at @NSSpain XIV 2026, currently taking place from 16 to 18 September 2026 in Logroño, Spain. Alex's presentation, “How to Prepare Your iOS SaMD for FDA Submission,” shared practical lessons from our own experience developing an iOS application as Software as a Medical Device (#SaMD). The session covered the documentation, Quality Management System (QMS), testing strategy, and privacy and security controls our team has implemented as we advance BlinkLab Dx1 toward FDA 510(k) submission.

What is next on BlinkLab’s path toward US commercialization? In a new Leadership Talks interview with @ECR_Australia, Dr. Henk-Jan Boele, BlinkLab's Managing Director and CEO, shares the latest updates on the Dx1 autism program, positive results from the Dx2 ADHD program, and key milestones ahead. Watch the full interview here: youtu.be/lTkEIaTdSDI?si=AvMP…

On Aug 28, BlinkLab welcomed Western Australian Minister Stephen Dawson MLC to Leiden. We discussed #MedTech, #DigitalHealth, WA’s clinical research ecosystem, NDIS changes, access to autism and ADHD assessment, and how BlinkLab could establish a meaningful presence in WA.

$BB1.ax - BlinkLab Limited (ASX:BB1) was pleased to present at the 20th Bioshares Biotech Summit last week in Queenstown, New Zealand. Representing the company were Dr Henk-Jan Boele (CEO, Managing Director and Co-Founder) and Mr Brian Leedman (Non-Executive Chairman), who had the pleasure of joining healthcare and biotechnology leaders from across the sectors in both Australia and New Zealand. As always, it was a spectacular event for all, and it was an honour for BlinkLab to be involved again.

BlinkLab (ASX:BB1) will pursue US approval of its algo-based attention deficit hyperactivity disorder (ADHD) diagnosis tool, having posted positive results from a European study. Read more: stockhead.com.au/health/heal… $BB1 #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to provide a recording from the Investor Webinar held on Wednesday, 5 August 2026 via Zoom. Dr Henk-Jan Boele (Co-Founder, Managing Director, and CEO) provided an update of the Company’s European ADHD study with Mental Care Group (MCG), including an overview of its results. About Mental Care Group and the European ADHD Study BlinkLab’s European ADHD study is a collaboration with Mental Care Group (MCG), the largest mental healthcare provider in the Netherlands, and the fifth largest in Europe, operating across approximately 150 locations and an expansive network of psychologists, psychiatrists, and other clinicians servicing over 80,000 patients annually. The current European ADHD study is a large-scale clinical study designed to evaluate BlinkLab’s objective measures against gold standard clinical diagnostic approaches for ADHD. 📺 Watch video - youtu.be/YD-Ch3dGTP0

BlinkLab Ltd (ASX:BB1, OTC:BKLBF, FRA:P41) has reported positive results from a European ADHD study, marking a major step toward expanding its smartphone-based diagnostic platform beyond autism. The study achieved sensitivity of 82% and specificity of 83% in children aged six to 17, supporting further development of BlinkLab Dx2, an artificial intelligence model designed to identify digital neurobehavioural markers associated with attention-deficit/hyperactivity disorder. Read more: proactiveinvestors.com.au/co… $BB1 #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to report results from its European case-control study of smartphone-based digital neurobehavioural biomarkers in children aged 6 through 17 years, both with and without attention-deficit/hyperactivity disorder (ADHD). The study achieved sensitivity of 82% and specificity of 83% (two key statistical measures that are used to evaluate the accuracy of diagnostic tests such as BlinkLab’s) relative to its clinical diagnostic reference standard. Read more: mcusercontent.com/67ac9e4f39… $BB1 #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to announce that it will be hosting an Investor Webinar on TODAY - Wednesday, 5 August 2026 at 11:00am AEST (9:00am AWST) via Zoom. Dr Henk-Jan Boele (Co-Founder, Managing Director, and CEO) will provide an update of the Company’s European ADHD study with Mental Care Group (MCG), including an overview of its results. 📆 Wednesday, 5 August 2026 at 11:00am AEST (9:00am AWST) 📌 REGISTRATION: janemorganmanagement-au.zoom… About Mental Care Group and the European ADHD Study BlinkLab’s European ADHD study is a collaboration with Mental Care Group (MCG), the largest mental healthcare provider in the Netherlands, and the fifth largest in Europe, operating across approximately 150 locations and an expansive network of psychologists, psychiatrists, and other clinicians servicing over 80,000 patients annually. The current European ADHD study is a large-scale clinical study designed to evaluate BlinkLab’s objective measures against gold standard clinical diagnostic approaches for ADHD.

BlinkLab's Managing Director and CEO, Henk-Jan Boele, presented at the TechKnow Conference in Melbourne, sharing insights into the Company’s expanding clinical study portfolio beyond its pivotal U.S. FDA 510(k) autism diagnostic program. Investors are welcome to reach out to Chairman Brian Leedman, who is presenting in Sydney today.

BlinkLab Limited (ASX:BB1) is pleased to provide its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2026. Read more: mcusercontent.com/67ac9e4f39… $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to provide an update on its expanding clinical study portfolio beyond its pivotal U.S. FDA 510(k) autism diagnostic program. While the Company's immediate priority remains the development and regulatory clearance of BlinkLab Dx1, it has strategically established a growing portfolio of collaborative studies designed to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions. Read more: mcusercontent.com/67ac9e4f39… $BB1.ax #awareness #autismspeaks

BlinkLab's Chairman, Brian Leedman, is pleased to be presenting at the upcoming Techknow Invest Roadshows in Melbourne and Sydney. Register via techknowinvestroadshow.com.a… $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to announce that a key patent underpinning its digital neurobehavioral assessment platform has been granted by the United States Patent and Trademark Office (USPTO). Read more: buff.ly/JG4dvs8 $BB1.ax #awareness #autismspeaks

BlinkLab (ASX:BB1) is pleased to announce a collaboration with Escuela Superior Politécnica de Chimborazo (“ESPOCH”) in Ecuador to support Proyecto Wiñay, a nationwide study program investigating autism, sensorimotor function, nutrition and gut microbiota in Ecuadorian children and adolescents. Read more: buff.ly/TT2SfdH $BB1.ax #awareness #autismspeaks